FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362700555> ?p ?o ?g. }

• W4362700555 abstract "Abstract Importance Investigating the role of pre-infection humoral immunity against Omicron BA.5 infection risk and long COVID development is critical to inform public health guidance. Objective To investigate the association between pre-infection immunogenicity after the third vaccine dose and the risks of Omicron BA.5 infection and long coronavirus disease. Design, Setting, and Participants This nested case-control analysis was conducted among tertiary hospital staff in Tokyo, Japan who donated blood samples in June 2022 (1 month before Omicron BA.5 dominant wave onset [July–September 2022]) approximately 6 months after receiving the third dose of the historical monovalent coronavirus disease 2019 mRNA vaccine. Exposures Live virus-neutralizing antibody titers against Wuhan and Omicron BA.5 (NT 50 ) and anti-SARS-CoV-2 spike protein antibody titers with Abbott (AU/mL) and Roche (U/mL) assays at pre-infection. Main Outcomes and Measures Symptomatic SARS-CoV-2 breakthrough infections during the Omicron BA.5 dominant wave vs. undiagnosed controls matched using a propensity score. Incidence of long COVID (persistent symptoms ≥4 weeks after infection) among breakthrough infection cases. Results Anti-spike antibody titers were compared between 243 breakthrough infection cases and their matched controls among the 2360 staff members who met the criteria. Neutralizing antibodies in 50 randomly selected matched pairs were measured and compared. Pre-infection anti-spike and neutralizing antibody titers were lower in breakthrough cases than in undiagnosed controls. Neutralizing antibody titers against Wuhan and Omicron BA.5 were 64% (95% CI: 42–77) and 72% (95% CI: 53–83) lower, respectively, in breakthrough cases than in undiagnosed controls. Individuals with previous SARS-CoV-2 infections were more frequent among undiagnosed controls than breakthrough cases (19.3% vs. 4.1%), and their neutralizing antibody titers were higher than those of infection-naïve individuals. Among the breakthrough cases, pre-infection antibody titers were not associated with the incidence of long COVID. Conclusions and Relevance Pre-infection immunogenicity against SARS-CoV-2 may play a role in protecting against the Omicron BA.5 infection, but not in preventing long COVID. Key Points Question Does pre-infection anti-SARS-CoV-2 humoral immunity protect against Omicron BA.5 infection and long-COVID development? Findings Pre-infection neutralizing antibody titers against Omicron BA.5 were lower in subsequent Omicron BA.5 breakthrough infection cases than in matched controls in this nested case-control study of healthcare workers who received the third dose of historical COVID-19 mRNA vaccines approximately 6 months prior. Pre-infection antibody titers could not predict the incidence of long COVID among breakthrough infection cases. Meaning Higher pre-infection humoral immunity approximately 6 months after the third vaccination may correlate with protection against Omicron BA.5 infection but not against long-COVID development." @default.
• W4362700555 created "2023-04-09" @default.
• W4362700555 creator A5001197457 @default.
• W4362700555 creator A5006409532 @default.
• W4362700555 creator A5012664443 @default.
• W4362700555 creator A5014601065 @default.
• W4362700555 creator A5023373849 @default.
• W4362700555 creator A5029414324 @default.
• W4362700555 creator A5032031868 @default.
• W4362700555 creator A5034448543 @default.
• W4362700555 creator A5044167258 @default.
• W4362700555 creator A5045100927 @default.
• W4362700555 creator A5051755149 @default.
• W4362700555 creator A5052832858 @default.
• W4362700555 creator A5055989025 @default.
• W4362700555 creator A5058847401 @default.
• W4362700555 creator A5059325051 @default.
• W4362700555 creator A5067354013 @default.
• W4362700555 creator A5072936823 @default.
• W4362700555 creator A5084560457 @default.
• W4362700555 creator A5088086085 @default.
• W4362700555 creator A5090856797 @default.
• W4362700555 date "2023-04-06" @default.
• W4362700555 modified "2023-10-16" @default.
• W4362700555 title "Pre-infection neutralizing antibodies, Omicron BA.5 breakthrough infection, and long COVID: a propensity score-matched analysis" @default.
• W4362700555 cites W2086493164 @default.
• W4362700555 cites W3133547117 @default.
• W4362700555 cites W3136955306 @default.
• W4362700555 cites W3162528078 @default.
• W4362700555 cites W4200579619 @default.
• W4362700555 cites W4221131277 @default.
• W4362700555 cites W4225470021 @default.
• W4362700555 cites W4226287603 @default.
• W4362700555 cites W4281291961 @default.
• W4362700555 cites W4283171904 @default.
• W4362700555 cites W4283319609 @default.
• W4362700555 cites W4286269470 @default.
• W4362700555 cites W4293214352 @default.
• W4362700555 cites W4295898295 @default.
• W4362700555 cites W4296784260 @default.
• W4362700555 cites W4296816614 @default.
• W4362700555 cites W4302009688 @default.
• W4362700555 cites W4308708308 @default.
• W4362700555 cites W4315779712 @default.
• W4362700555 cites W4316014106 @default.
• W4362700555 cites W4317696178 @default.
• W4362700555 cites W4317743572 @default.
• W4362700555 cites W4321369243 @default.
• W4362700555 cites W4323808759 @default.
• W4362700555 doi "https://doi.org/10.1101/2023.04.05.23288162" @default.
• W4362700555 hasPublicationYear "2023" @default.
• W4362700555 type Work @default.
• W4362700555 citedByCount "0" @default.
• W4362700555 crossrefType "posted-content" @default.
• W4362700555 hasAuthorship W4362700555A5001197457 @default.
• W4362700555 hasAuthorship W4362700555A5006409532 @default.
• W4362700555 hasAuthorship W4362700555A5012664443 @default.
• W4362700555 hasAuthorship W4362700555A5014601065 @default.
• W4362700555 hasAuthorship W4362700555A5023373849 @default.
• W4362700555 hasAuthorship W4362700555A5029414324 @default.
• W4362700555 hasAuthorship W4362700555A5032031868 @default.
• W4362700555 hasAuthorship W4362700555A5034448543 @default.
• W4362700555 hasAuthorship W4362700555A5044167258 @default.
• W4362700555 hasAuthorship W4362700555A5045100927 @default.
• W4362700555 hasAuthorship W4362700555A5051755149 @default.
• W4362700555 hasAuthorship W4362700555A5052832858 @default.
• W4362700555 hasAuthorship W4362700555A5055989025 @default.
• W4362700555 hasAuthorship W4362700555A5058847401 @default.
• W4362700555 hasAuthorship W4362700555A5059325051 @default.
• W4362700555 hasAuthorship W4362700555A5067354013 @default.
• W4362700555 hasAuthorship W4362700555A5072936823 @default.
• W4362700555 hasAuthorship W4362700555A5084560457 @default.
• W4362700555 hasAuthorship W4362700555A5088086085 @default.
• W4362700555 hasAuthorship W4362700555A5090856797 @default.
• W4362700555 hasBestOaLocation W43627005551 @default.
• W4362700555 hasConcept C120665830 @default.
• W4362700555 hasConcept C121332964 @default.
• W4362700555 hasConcept C126322002 @default.
• W4362700555 hasConcept C159047783 @default.
• W4362700555 hasConcept C159654299 @default.
• W4362700555 hasConcept C203014093 @default.
• W4362700555 hasConcept C22889606 @default.
• W4362700555 hasConcept C2779134260 @default.
• W4362700555 hasConcept C2779261636 @default.
• W4362700555 hasConcept C2780868878 @default.
• W4362700555 hasConcept C3007834351 @default.
• W4362700555 hasConcept C3008058167 @default.
• W4362700555 hasConcept C32611913 @default.
• W4362700555 hasConcept C524204448 @default.
• W4362700555 hasConcept C61511704 @default.
• W4362700555 hasConcept C71924100 @default.
• W4362700555 hasConceptScore W4362700555C120665830 @default.
• W4362700555 hasConceptScore W4362700555C121332964 @default.
• W4362700555 hasConceptScore W4362700555C126322002 @default.
• W4362700555 hasConceptScore W4362700555C159047783 @default.
• W4362700555 hasConceptScore W4362700555C159654299 @default.
• W4362700555 hasConceptScore W4362700555C203014093 @default.
• W4362700555 hasConceptScore W4362700555C22889606 @default.
• W4362700555 hasConceptScore W4362700555C2779134260 @default.
• W4362700555 hasConceptScore W4362700555C2779261636 @default.

• next